Literature DB >> 23880784

A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome.

Stephen J Eyler1, Nicole C Meyer, Yuzhou Zhang, Xue Xiao, Carla M Nester, Richard J H Smith.   

Abstract

BACKGROUND: Mutations in complement factor H (CFH) are associated with complement dysregulation and the development of an aggressive form of atypical hemolytic uremic syndrome (aHUS) that progresses to end-stage renal disease (ESRD) and in most patients has a high rate of recurrence following transplantation. Sequence analysis of CFH and its downstream complement factor H-related genes (CFHR1-5) reveals several macrohomologous blocks caused by large genomic duplications. This high degree of sequence identity renders this area susceptible to nonallelic homologous recombination (NAHR) events, resulting in large-scale deletions, duplications, and the generation of hybrid CFH genes. CASE-DIAGNOSIS: Here, we report the finding of a novel CFHR1/CFH hybrid gene created by a de novo NAHR event in a 14-year-old girl with aHUS. The resulting fusion protein contains the first three short consensus repeats (SCRs) of CFHR1 and the terminal two SCRs of CFH.
CONCLUSIONS: This finding demonstrates a novel pathogenic mechanism for the development of aHUS. Additionally, since standard Sanger sequencing is unable to detect such rearrangements, all aHUS patients should receive comprehensive genetic screening that includes analysis of copy number variation in order to identify patients with poor clinical prognoses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23880784      PMCID: PMC4433496          DOI: 10.1007/s00467-013-2560-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

2.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

3.  A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome.

Authors:  Tara K Maga; Nicole C Meyer; Craig Belsha; Carla J Nishimura; Yuzhou Zhang; Richard J H Smith
Journal:  Nephrol Dial Transplant       Date:  2010-10-25       Impact factor: 5.992

4.  Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.

Authors:  V Chatelet; V Frémeaux-Bacchi; T Lobbedez; M Ficheux; B Hurault de Ligny
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

5.  Dense deposit disease associated with monoclonal gammopathy of undetermined significance.

Authors:  Sanjeev Sethi; William R Sukov; Yuzhou Zhang; Fernando C Fervenza; Donna J Lager; Dylan V Miller; Lynn D Cornell; Srivilliputtur G Santhana Krishnan; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2010-09-15       Impact factor: 8.860

6.  Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome.

Authors:  Tara K Maga; Carla J Nishimura; Amy E Weaver; Kathy L Frees; Richard J H Smith
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

7.  Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.

Authors:  Mihály Józsi; Christoph Licht; Stefanie Strobel; Svante L H Zipfel; Heiko Richter; Stefan Heinen; Peter F Zipfel; Christine Skerka
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

8.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

Review 9.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

10.  Atypical haemolytic uraemic syndrome associated with a hybrid complement gene.

Authors:  Julian P Venables; Lisa Strain; Danny Routledge; David Bourn; Helen M Powell; Paul Warwicker; Martha L Diaz-Torres; Anne Sampson; Paul Mead; Michelle Webb; Yves Pirson; Michael S Jackson; Anne Hughes; Katrina M Wood; Judith A Goodship; Timothy H J Goodship
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

View more
  19 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

2.  Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA.

Authors:  Jesús García-Fernández; Susana Vilches-Arroyo; Leticia Olavarrieta; Julián Pérez-Pérez; Santiago Rodríguez de Córdoba
Journal:  Methods Mol Biol       Date:  2021

3.  Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.

Authors:  Sami Alobaidi; Ammar AlDabbagh; Amany Alamoudi; Murad Almowarey; Ahmed Akl
Journal:  CEN Case Rep       Date:  2019-02-04

Review 4.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

5.  Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces.

Authors:  Qian Chen; Melanie Manzke; Andrea Hartmann; Maike Büttner; Kerstin Amann; Diana Pauly; Michael Wiesener; Christine Skerka; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2015-10-02       Impact factor: 10.121

6.  Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family.

Authors:  Stuart Cantsilieris; Bradley J Nelson; John Huddleston; Carl Baker; Lana Harshman; Kelsi Penewit; Katherine M Munson; Melanie Sorensen; AnneMarie E Welch; Vy Dang; Felix Grassmann; Andrea J Richardson; Robyn H Guymer; Tina A Graves-Lindsay; Richard K Wilson; Bernhard H F Weber; Paul N Baird; Rando Allikmets; Evan E Eichler
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

Review 7.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 9.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

10.  Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.

Authors:  Elena Goicoechea de Jorge; Agustín Tortajada; Sheila Pinto García; Sara Gastoldi; Héctor Martín Merinero; Jesús García-Fernández; Emilia Arjona; Mercedes Cao; Giuseppe Remuzzi; Marina Noris; Santiago Rodríguez de Córdoba
Journal:  J Am Soc Nephrol       Date:  2017-10-09       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.